Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Jingjing Li; Wen Bi; Fang Lu; Bei Pan; Mengqiu Xiong; Lubanga Nasifu; Zhenlin Nie; Bangshun He

doi:10.1186/s12885-023-10865-8

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

BMC Cancer. 2023 Jun 5;23(1):509. doi: 10.1186/s12885-023-10865-8.

Authors

Jingjing Li^#¹, Wen Bi^#¹, Fang Lu^{2

3}, Bei Pan⁴, Mengqiu Xiong¹, Lubanga Nasifu^{1

5}, Zhenlin Nie^{6

7}, Bangshun He^{8

9}

Affiliations

¹ Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
² School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
³ Department of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China.
⁴ Medical College, Southeast University, Nanjing, 210006, China.
⁵ Department of Biology, Muni University, Arua, Uganda.
⁶ Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. Zhenlinnie@126.com.
⁷ Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210006, China. Zhenlinnie@126.com.
⁸ Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. bhe@njmu.edu.cn.
⁹ Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210006, China. bhe@njmu.edu.cn.

^# Contributed equally.

Abstract

Objective: E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data.

Method: PubMed, Web of Science and CNKI database were searched until May 31^th, 2022 by using key words to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio and 95% confidence interval was calculated with Stata17.0 software.

Result: A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I² = 95.3%, *P_{Heterogeneity} = 0.000) and disease-free survival (HR = 1.41, I² = 95.2%, *P_{Heterogeneity} = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper.

Conclusion: E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter overall survival and disease-free survival.

Keywords: Breast cancer; Cancer; Disease-free survival; E2F1; Gene expression; Meta-analysis; Overall survival; Prognosis.

Publication types

Meta-Analysis

MeSH terms

Disease-Free Survival
E2F1 Transcription Factor / genetics
E2F1 Transcription Factor / metabolism
Female
Gene Expression
Humans
Neoplasms* / genetics
Neoplasms* / metabolism
Prognosis
Progression-Free Survival

Substances

E2F1 protein, human
E2F1 Transcription Factor